Key takeaway: Emami Limited reported a consolidated revenue growth of 15% to ₹1,039 crore for the quarter ended June 30, 2026. The domestic business grew by 20%, with a like-to-like growth of 12% and volume growth of 8%. However, the international business declined by 12% due to disruptions in West Asia. EBITDA increased by 6% to ₹226 crore, despite rising input costs, which led to a contraction in gross margins by 360 basis points to 65.8%. The company made strategic investments, including increasing its stake in Axiom Ayurveda and acquiring a majority stake in IncNut. Management highlighted the strong performance of the Strategic Investments portfolio, which grew by 61% and now contributes approximately 18% of domestic business. The earnings call emphasized the resilience of Emami's diversified portfolio and the ongoing channel transformation efforts, with organized channels growing by 19%.

Key takeaway: On May 21, 2026, Emami Limited held its Q4 FY '26 earnings conference call, where management discussed the company's financial results for the quarter and the full year ending March 31, 2026. Management reported a consolidated revenue of INR 925 crores for Q4, a decline of 4% year-over-year, primarily attributed to a weak summer portfolio, which saw a 22% decline. Despite these challenges, the domestic business excluding summer products grew by 11%. Gross margins improved to 68.4%, and profit after tax was reported at INR 143 crores, down 12%. Management highlighted strategic investments and acquisitions, including Axiom and IncNut, aimed at driving growth in high-margin categories. The international business faced a 5% decline due to geopolitical issues, but management expressed confidence in future growth. The call concluded with management emphasizing their focus on strengthening core brands and enhancing omnichannel capabilities.

Key takeaway: Emami Limited reported its audited financial results for Q4FY26 and FY26, highlighting a 4% decline in consolidated revenues and a 15% drop in EBITDA. The domestic portfolio, excluding the summer segment, grew by 11%, while international revenues fell by 5% due to geopolitical disruptions. Management noted that the quarter faced challenges from unfavorable seasonal conditions and external geopolitical factors, but emphasized the resilience of the core domestic business. Strategic investments were made in Axiom Ayurveda and IncNut to enhance future growth. The company declared interim dividends totaling ₹10 per share, reflecting confidence in its business resilience. Gross margins improved to 68.4%, attributed to effective cost management and increased advertising spend. The management expressed a commitment to long-term growth and strategic expansion into new-age FMCG segments, despite the challenges faced during the year.

Key takeaway: During the earnings call for Q3 FY26, management reported a strong performance with consolidated net sales growing by 11% to INR 1,152 crores. The domestic business achieved an 11% growth, driven by a 9% volume increase, with key brands like BoroPlus and Kesh King performing well. The company noted a favorable winter season that boosted sales in its winter portfolio and health care products. Management highlighted a strategic focus on innovation and premiumization, with digital marketing now accounting for nearly 50% of media spending. Gross margins improved to 70.6%, and EBITDA grew by 13% to INR 384 crores. A second interim dividend of 600% was declared, reflecting confidence in business performance. Management expressed optimism about future growth, particularly in rural markets, and indicated that the reduction in GST rates would support brand growth. The call concluded with a Q&A session addressing various operational aspects and market conditions.

Key takeaway: The investor presentation dated February 6, 2026, provided an overview of Emami Limited's performance and strategic initiatives. Management reported resilient performance despite macroeconomic challenges, achieving revenue growth in line with industry trends and maintaining leadership in key categories. The presentation highlighted a 6% increase in consolidated revenues and an 8% rise in EBITDA for FY25. Key brands such as Navratna and Dermicool showed significant growth, with a focus on diversifying core brands from niche to mainstream markets. Management emphasized the importance of digital channels, with D2C brands nearly doubling their revenue. The company also outlined its inorganic growth strategy, focusing on strategic investments in startups and acquisitions. The presentation noted a disciplined approach to capital deployment, with a strong cash position as of December 31, 2025. Overall, the document conveyed a comprehensive view of the company's operational strategies and financial metrics.

Key takeaway: Emami Limited reported strong financial results for the third quarter and nine months ended December 31, 2025, with consolidated net sales growing by 11% to ₹1,147 crore. The domestic business contributed to this growth with an 11% increase, driven by a 9% rise in volume. The company launched several new products, including Kesh King Gold Advanced Hair Growth Serum and BoroPlus Deeply Moisturising Lip Balm, to cater to evolving consumer needs. Gross margins improved to 70.6%, and EBITDA grew by 13% to ₹384 crore, with EBITDA margins expanding to 33.4%. The Board declared a second interim dividend of 600%, amounting to ₹6 per share. Management highlighted the resilience of rural demand and the gradual recovery of urban demand, alongside a successful omnichannel strategy that contributed to revenue growth. The international business also saw a 9% increase in sales, supported by new product launches in key markets.